David Escors

7.5k total citations
128 papers, 5.5k citations indexed

About

David Escors is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, David Escors has authored 128 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Immunology, 69 papers in Oncology and 26 papers in Molecular Biology. Recurrent topics in David Escors's work include Immunotherapy and Immune Responses (53 papers), Cancer Immunotherapy and Biomarkers (45 papers) and Immune Cell Function and Interaction (32 papers). David Escors is often cited by papers focused on Immunotherapy and Immune Responses (53 papers), Cancer Immunotherapy and Biomarkers (45 papers) and Immune Cell Function and Interaction (32 papers). David Escors collaborates with scholars based in Spain, United Kingdom and Belgium. David Escors's co-authors include Karine Breckpot, Grazyna Kochan, Hugo Arasanz, Miren Zuazo, Luis Enjuanes, María Gato, Alessio Lanna, Javier Ortego, Arne N. Akbar and Ana Bocanegra and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

David Escors

125 papers receiving 5.4k citations

Peers

Countries citing papers authored by David Escors

Since Specialization

Citations

This map shows the geographic impact of David Escors's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Escors with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Escors more than expected).

Fields of papers citing papers by David Escors

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Escors. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Escors. The network helps show where David Escors may publish in the future.

Co-authorship network of co-authors of David Escors

This figure shows the co-authorship network connecting the top 25 collaborators of David Escors. A scholar is included among the top collaborators of David Escors based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Escors. David Escors is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets 2024 ·EMBO Molecular Medicine ·Luisa Chocarro, Ester Blanco, Leticia Fernández, Maider Garnica, Miren Zuazo, María Jesús García García, Ana Bocanegra, Miriam Echaide, Colette M. Johnston, Carolyn Edwards, James Legg, Andrew J. Pierce, Hugo Arasanz, G. Fernández-Hinojal, Ruth Vera, Karina Ausín, Enrique Santamaría, Joaquín Fernández‐Irigoyen, Grazyna Kochan, David Escors	11
2	Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events 2023 ·Cancers ·Íñigo Les, (unknown), (unknown), (unknown), Lucía Teijeira, Virginia Arrazubi, (unknown), (unknown), (unknown), Grazyna Kochan, David Escors	46
3	Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors 2023 ·International Journal of Molecular Sciences ·Ester Blanco, Luisa Chocarro, Leticia Fernández, Ana Bocanegra, Hugo Arasanz, Miriam Echaide, Maider Garnica, Sergio Piñeiro‐Hermida, Grazyna Kochan, David Escors	11
4	Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer 2023 ·International Journal of Molecular Sciences ·Hugo Arasanz, Luisa Chocarro, Leticia Fernández, Ester Blanco, Ana Bocanegra, Miriam Echaide, Ibone Labiano, Ana E. Huerta, María Alsina, Ruth Vera, David Escors, Grazyna Kochan	6
5	LAG-3 Role in Cardiovascular Diseases 2022 ·Luisa Chocarro, Ester Blanco, Hugo Arasanz, (unknown), Miriam Echaide, Maider Garnica, Pablo Ramos, (unknown), Grazyna Kochan, David Escors	1
6	How Can We Improve the Vaccination Response in Older People? Part II: Targeting Immunosenescence of Adaptive Immunity Cells 2022 ·International Journal of Molecular Sciences ·Maider Garnica, Anna Aiello, Mattia Emanuela Ligotti, Giulia Accardi, Hugo Arasanz, Ana Bocanegra, Ester Blanco, Anna Calabrò, Luisa Chocarro, Miriam Echaide, Grazyna Kochan, Leticia Fernández, Pablo Ramos, Fanny Pojero, Nahid Zareian, Sergio Piñeiro‐Hermida, Farzin Farzaneh, Giuseppina Candore, Calogero Caruso, David Escors	11
7	CAR-T Cells for the Treatment of Lung Cancer 2022 ·Life ·Luisa Chocarro, Hugo Arasanz, Leticia Fernández, Ester Blanco, Miriam Echaide, Ana Bocanegra, Lucía Teijeira, Maider Garnica, Idoia Morilla, (unknown), Sergio Piñeiro‐Hermida, Pablo Ramos, Juan José Lasarte, Ruth Vera, Grazyna Kochan, David Escors	14
8	Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer 2022 ·Cancers ·Hugo Arasanz, Ana Bocanegra, Idoia Morilla, Joaquín Fernández‐Irigoyen, (unknown), Lucía Teijeira, Maider Garnica, Ester Blanco, Luisa Chocarro, Karina Ausín, Miren Zuazo, G. Fernández-Hinojal, Miriam Echaide, Leticia Fernández, Sergio Piñeiro‐Hermida, Pablo Ramos, Laura Mezquita, David Escors, Ruth Vera, Grazyna Kochan	26
9	Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy 2022 ·International Journal of Molecular Sciences ·David Escors, Ana Bocanegra, Luisa Chocarro, Ester Blanco, Sergio Piñeiro‐Hermida, Maider Garnica, Leticia Fernández, Ruth Vera, Hugo Arasanz, Grazyna Kochan	11
10	How Can We Improve Vaccination Response in Old People? Part I: Targeting Immunosenescence of Innate Immunity Cells 2022 ·International Journal of Molecular Sciences ·Anna Aiello, Mattia Emanuela Ligotti, Maider Garnica, Giulia Accardi, Anna Calabrò, Fanny Pojero, Hugo Arasanz, Ana Bocanegra, Ester Blanco, Luisa Chocarro, Miriam Echaide, Leticia Fernández, Pablo Ramos, Sergio Piñeiro‐Hermida, Grazyna Kochan, Nahid Zareian, Farzin Farzaneh, David Escors, Calogero Caruso, Giuseppina Candore	16
11	Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination 2022 ·Cancers ·Miriam Echaide, Ibone Labiano, (unknown), Ángela Fernández de Lascoiti, (unknown), Maider Garnica, Pablo Ramos, Luisa Chocarro, Leticia Fernández, Hugo Arasanz, Ana Bocanegra, Ester Blanco, Sergio Piñeiro‐Hermida, (unknown), Ruth Vera, María Alsina, David Escors, Grazyna Kochan	9
12	Hyperprogressive Disease: Main Features and Key Controversies 2021 ·International Journal of Molecular Sciences ·Hugo Arasanz, Miren Zuazo, Ana Bocanegra, Luisa Chocarro, Ester Blanco, Maite Martínez, Idoia Morilla, (unknown), Lucía Teijeira, (unknown), Miriam Echaide, N. Castro Unanua, Leticia Fernández, Maider Garnica, Pablo Ramos, David Escors, Grazyna Kochan, Ruth Vera	20
13	Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition 2020 ·Cancers ·Hugo Arasanz, Carlos Hernández, Ana Bocanegra, Luisa Chocarro, Miren Zuazo, María Gato, Karina Ausín, Enrique Santamaría, Joaquín Fernández‐Irigoyen, (unknown), Eva Santamaría, Carlos M. Rodríguez‐Ortigosa, Idoia Blanco‐Luquin, Ruth Vera, David Escors, Grazyna Kochan	7
14	Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics 2020 ·Cancers ·Hugo Arasanz, Miren Zuazo, Ana Bocanegra, María Gato, (unknown), Idoia Morilla, (unknown), Berta Hernández, (unknown), (unknown), Carlos Hernández, Luisa Chocarro, Lucía Teijeira, Ruth Vera, Grazyna Kochan, David Escors	58
15	Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies 2020 ·International Journal of Molecular Sciences ·Carlos Hernández, Hugo Arasanz, Luisa Chocarro, Ana Bocanegra, Miren Zuazo, G. Fernández-Hinojal, Ester Blanco, Ruth Vera, David Escors, Grazyna Kochan	27
16	Functional systemic CD 4 immunity is required for clinical responses to PD ‐L1/ PD ‐1 blockade therapy 2019 ·EMBO Molecular Medicine ·Miren Zuazo, Hugo Arasanz, G. Fernández-Hinojal, María Jesús García-Granda, María Gato, Ana Bocanegra, Maite Martínez, Berta Hernández, Lucía Teijeira, Idoia Morilla, María José Lecumberri, Ángela Fernández de Lascoiti, Ruth Vera, Grazyna Kochan, David Escors	143
17	PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer 2019 ·International Journal of Molecular Sciences ·Ana Bocanegra, G. Fernández-Hinojal, (unknown), Hugo Arasanz, María Jesús García-Granda, Carlos Hernández, María Ibáñez-Vea, (unknown), (unknown), María José Lecumberri, Ángela Fernández de Lascoiti, Lucía Teijeira, Idoia Morilla, Ruth Vera, David Escors, Grazyna Kochan	62
18	Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells 2013 ·UCL Discovery (University College London) ·Karine Breckpot, (unknown), Brenda De Keersmaecker, Carlo Heirman, Jurgen Corthals, Thérèse Liechtenstein, David Escors, K Thielemans	5
19	Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen‐specific regulatory T cells, and suppresses experimental inflammatory arthritis 2010 ·Arthritis & Rheumatism ·Frederick Arce, Karine Breckpot, Holly Stephenson, Katarzyna Karwacz, Michael R. Ehrenstein, Mary Collins, David Escors	54
20	Selective ERK activation suppresses inflammatory arthritis via tolerogenic dendritic cells and antigen-specific regulatory T cells 2010 ·VUBIR (Vrije Universiteit Brussel) ·Frederick Arce, Karine Breckpot, Holly Stephenson, Katarzyna Karwacz, Mary Collins, David Escors	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact